Skip to main content
Journal ArticleOPEN ACCESS

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series

  • Vijayan S
  • Hwangbo K
  • Barkham N
Clinical Case Reports (2022) 10(1)
DOI: 10.1002/ccr3.5233
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.

Cite

CITATION STYLE

APA

Vijayan, S., Hwangbo, K., & Barkham, N. (2022). Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series. Clinical Case Reports, 10(1). https://doi.org/10.1002/ccr3.5233

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free